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ABBREVIATIONS
ABL Abelson murine leukemia viral oncogene homolog 1
ACVR2 activin type 2 receptor
APC adenomatous polyposis coli
BCR breakpoint cluster region
BLM Bloom syndrome gene
BRAF v-raf murine sarcoma viral oncogene homolog B1
CD44 cell-surface glycoprotein (indian blood group)
CDKN2A cyclin-dependent kinase inhibitor 2A
CIMP CpG island methylator phenotype
CIN chromosomal instability
CTNNB1 β-catenin gene
DCC deleted in colorectal cancer
ESR1 estrogen receptor alpha
FAP familial adenomatous polyposis
GSTP1 glutathione S-transferase pi
HNPCC hereditary nonpolyposis colorectal cancer
InSiGHT International Society for gastrointestinal Hereditary Tumors
IGFIIR insulin-like growth factor 2 receptor
KRAS Kirsten rat sarcoma viral oncogene homolog
LOH loss of heterozygosity
MBD4 methyl-CpG binding domain protein 4
MINT methylated in tumors 1
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MGMT O-6-methylguanine-DNA methyltransferase
MLH1, 3 human mutL homolog 1, 3
MLPA multiplex ligation-dependent probe amplification
MMR mismatch repair
MRE11A meiotic recombination 11 homolog A
MSH2, 3, 6 human mutS homolog 2, 3, 6
MSI(-H) microsatellite instability (-high)
MS-MLPA methylation specific MLPA
MSP methylation specific sequencing
MSS microsatellite stable
MYH mutY homolog (E. coli)
PTEN phosphate and tensin homolog
RASSF1 ras association domain family 1
Rb1 Retinoblastoma 1
RET RET proto-oncogene, “rearranged during transfection”
SNuPE single nucleotide primer extension
SP-PCR small-pool PCR
SSCP single strand conformation polymorphism
TGFβRII transforming growth factor receptor II
THBS1 thrombospondin 1
TIMP3 metallopeptidase inhibitor 3
TP53 tumor protein 53
VHL Von Hippel-Lindau gene
Wnt wingless-type
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ABSTRACT
Hereditary non-polyposis colorectal carcinoma (HNPCC; Lynch syndrome)
is among the most common hereditary cancers in man and a model of can-
cers arising through deficient DNA mismatch repair (MMR). It is inherited
in a dominant manner with predisposing germline mutations in the MMR
genes, mainly MLH1, MSH2, MSH6 and PMS2. Both copies of the MMR
gene need to be inactivated for cancer development. Since Lynch syndrome
family members are born with one defective copy of one of the MMR genes
in their germline, they only need to acquire a so called “second hit” to
inactivate the MMR gene. Hence, they usually develop cancer at an early
age. MMR gene inactivation leads to accumulation of mutations particu-
larly in short repeat tracts, known as microsatellites, causing microsatellite
instability (MSI). MSI is the hallmark of Lynch syndrome tumors, but is
present in approximately 15% of sporadic tumors as well.
There are several possible mechanisms of somatic inactivation (i.e. the
“second hit”) of MMR genes, for instance deletion of the wild-type copy,
leading to ’loss of heterozygosity’ (LOH), methylation of promoter regions
necessary for gene transcription, or mitotic recombination or gene conver-
sion. In the Lynch syndrome tumors carrying germline mutations in the
MMR gene, LOH was found to be the most frequent mechanism of so-
matic inactivation in the present study. We also studied MLH1 /MSH2
deletion carriers and found that somatic mutations identical to the ones in
the germline occurred frequently in colorectal cancers and were also present
in extracolonic Lynch syndrome-associated tumors. Chromosome-specific
marker analysis implied that loss of the wild-type allele predominantly oc-
curs through locus-restricted recombinational events, i.e., gene conversion,
rather than mitotic recombination or deletion of the respective gene locus.
Lynch syndrome patients are predisposed to certain types of cancers,
the most common being colorectal and endometrial cancer. Gastric cancer
is the second most common extracolonic malignancy in individuals with
Lynch syndrome but is also relatively common in the general population.
Therefore, our aim was to study whether or not gastric cancer is a true
Lynch syndrome spectrum malignancy. The molecular and clinicopatho-
logical profiles of gastric cancers from Lynch syndrome mutation carriers
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were evaluated and compared with the profiles of sporadic gastric can-
cers. We found that gastric cancers from Lynch syndrome mutation car-
riers resembled sporadic intestinal MSI gastric cancers, except that MLH1
promoter methylation was absent and the general methylation index was
lower, suggesting similar, but not identical, developmental pathways. All
of these lacked the mismatch repair protein corresponding to the germline
mutation and displayed high MSI. The present molecular evidence, com-
bined with the previous demonstration of an increased incidence relative
to the general population, justify considering gastric cancers as true Lynch
syndrome spectrum malignancies.
Currently, it is not clear why certain tissues are more susceptible to
cancer in Lynch syndrome than others. We addressed this issue by deter-
mining the molecular profiles for different tumors from a nationwide cohort
of Lynch syndrome families. Here we focused on some less prevalent can-
cers, affecting the brain and urinary tract, and compared their molecular
characteristics to those of the most common cancers, colorectal, gastric
and endometrial adenocarcinomas, from the same families. Despite origin
from verified MMR gene mutation carriers, the frequency of high-level mi-
crosatellite instability in tumors varied between high (100-96% for ureter,
stomach and colon), intermediate (63-60% for endometrium and bladder)
and low (25-0% for kidney and brain). Our results implied that different
Lynch syndrome tumors develop along different routes. Uroepithelial can-
cers of the ureter (and bladder to lesser extent) share many characteristics
of MMR deficiency-driven tumorigenesis, whereas brain tumors and kidney
adenocarcinomas follow separate pathways.
In about one-third of families suspected of Lynch syndrome, mutations
in MMR genes are not found. Therefore, we studied large genomic rear-
rangements and constitutive promoter hypermethylation as explanations
for families/cases lacking germline mutations in MMR genes by conven-
tional screening but which displayed loss of MLH1, MSH2 or MSH6 ex-
pression in tumor tissue. According to our results, large genomic deletions,
mainly in MSH2, and germline epimutations in MLH1, together explain a
significant fraction of point mutation-negative families suspected of Lynch
syndrome and are associated with characteristic clinical and family features.
Our findings have important implications in the diagnosis and management
of Lynch syndrome families.
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REVIEW OF THE
LITERATURE
1 Cancer
Every fourth person in Finland will be affected by cancer at some point of
their life, and the risk of cancer increases with age. Annually approximately
24000 persons are diagnosed with cancer, of which half will be cured. The
prognosis varies depending on the type and the stage of the cancer. In
Finland, there are approximately 170000 people who are living with cancer
(The Finnish Cancer Registry, www.cancerregistry.fi, updated May 2008).
However, since both cancer diagnostics and treatments are continuously
improving, more than half of all cancer patients can be cured today (Finnish
cancer organizations, www.cancer.fi).
Cancer is a disease with increased incidence in countries with higher life
expectancy, since cancer develops over a long time and affects mainly el-
derly people. In Finland, the most prevalent cancers in males are prostate,
lung and bronchial, colon, and urinary bladder. In females, breast cancer
is by far the most common cancer type, followed by cancer of colon, en-
dometrium, and lungs (The Finnish Cancer Registry, www.cancerregistry.fi,
May 2008).
The human body is composed of approximately one hundred trillion
cells (1014), thus maintenance of cell homeostasis is crucial, and failure of
this regulation may lead to the formation of tumors. Cancer is not a sin-
gle disease but rather a collective name for a group of diseases that arise
from cells with uncontrolled growth, acquired immortality and invading and
metastasizing capacity (Hanahan and Weinberg, 2000). Primary cancer is
according to the tissue it originates from, for instance colorectal cancer af-
fects large intestine and rectum, gastric cancer originates from the stomach,
and endometrial cancer originates from the endometrium. Similarly, classi-
fication of cancer is based on the tissue from which it originates; carcinomas
are derived from epithelia; sarcomas from connective and muscle tissue; and
leukemia and lymphoma from blood and lymphatic tissue (Weinberg, 2007)
(Table 1).
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Table 1: Classification of solid tumors according to tissue of origin (modified
from Syo¨pa¨ja¨rjesto¨t, Tietoa Syo¨va¨sta¨, www.cancer.fi)
Type of tissue Benign Malignant
Epithelial tissue
lining epithelium papilloma carcinoma
glands & lobules adenoma adenocarcinoma
Connective tissue
& muscle tissue
dense connective tissue fibroma fibrosarcoma
cartilage chondroma chondrosarcoma
bone osteoma osteosarcoma
smooth muscle leiomyoma leiomyosarcoma
skeletal muscle rhabdomyoma rhabdomyosarcoma
Neuronal tissue
glial tissue glioma glioblastoma
meninges meningioma meningial sarcoma
Cells in different tissues contain the same genetic material that orches-
trates cell growth, proliferation, differentiation, as well as cell death. The
process of tumorigenesis is proposed to include six essential alterations in
cell physiology, including self-sufficiency in growth signals, insensitivity to
growth inhibiting signals, evasion of apoptosis, unlimited potential to repli-
cate, continual angiogenesis, and tissue invasion and metastasis (Hanahan
and Weinberg, 2000). Most of these changes occur through changes in the
genome, and therefore, cancer is considered a genetic disease. In spite of
being a genetic disease, a great majority of cancers are not hereditary.
Numerous environmental factors have been associated with develop-
ment of cancer, for instance a clear association has been observed between
carcinogens from tobacco smoking and lung cancer (Brennan et al., 2006).
Most cancers arise as a result of both genetic and environmental factors
(Potter, 1999).
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2 Cancer Genetics
2.1 Oncogenes and tumor suppressors
Cancer critical genes can be grouped according to their normal function in a
cell. Proto-oncogenes are genes that have a role in for example regulation of
cellular growth, proliferation and differentiation. Proto-oncogenes may be
activated and become oncogenes through point mutation, amplification or
translocation. Oncogenes are dominantly inherited, as only one mutation
is sufficient cause altered cell function; however, oncogenes are rarely the
cause of inherited cancer susceptibilities (Aittomaki and Peltomaki, 2006).
Tumor suppressors, on the other hand, are genes that when inactivated
no longer inhibit cell proliferation in the case of, for instance, DNA damage,
and thus give the tumor a growth advantage. Knudson observed that tu-
mor suppressor genes are recessive genes requiring “two hits” (both alleles
to become inactivated) for cancer development. Tumor suppressors have
been described in several hereditary forms of cancer, the “first hit” being
inherited and the “second hit” occurring in somatic cells (Knudson, 1996)
(Figure 1).
Tumor suppressor genes can further be divided into gatekeepers, care-
takers, and landscapers (Kinzler and Vogelstein, 1997; Kinzler and Vogel-
stein, 1998). Gatekeepers directly inhibit growth or promote cell death,
an example being the APC gene that when mutated leads to familial ade-
nomatous polyposis coli (FAP). Caretakers, in contrast, do not directly
promote tumor development, but their inactivation leads to genetic insta-
bility that in turn causes increased mutation rate in both oncogenes and
tumor suppressor genes, which contributes to tumorigenesis. An example
of caretaker genes are the mismatch repair (MMR) genes that predispose to
Lynch syndrome. Landscaper genes, as the name implies, indirectly causes
cancer by changing the landscape, that is, the microenvironment, making
it more advantageous for tumor formation. This phenomenon has been ob-
served in colon cancer where the abnormal stromal environment affects the
development and growth of epithelial cells, leading to neoplastic formation
(Ishiguro et al., 2006).
2.2 Genetic instability
During normal cell division, spontaneous mutations occur at a rate of ap-
proximately 3×10−13 per base pair per cell division. However, normal mu-
tation rates are not sufficient to generate a cancer cell from a pre-existing
normal cell (Lengauer et al., 1998; Hanahan and Weinberg, 2000). Based
on the requirement of several mutations for tumorigenesis to occur and the
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fact that most cancers harbor a large number of genetic and/or epigenetic
changes, it is not surprising that different experiments show that cancer
may contain more than 10,000 genetic and epigenetic changes (Stoler et
al., 1999). A study on breast and colorectal cancers revealed that indi-
vidual tumors accumulate an average of about 90 mutant genes but that
only a subset of these contribute to the neoplastic process (Sjoblom et al.,
2006). This has led to the hypothesis that genomic instability is required
for development of sporadic cancers. The instability is assumed to be due
to an increase in gene mutation rates or to an increase in the rate of pro-
duction of chromosomal abnormalities (Loeb, 1991; Loeb et al., 2003). In
most cancers the instability is observed at the chromosomal level (chro-
mosomal instability) but a small share of cancers also display instability
in short repetitive DNA sequences, known as microsatellites (microsatellite
instability) (Lengauer et al., 1998).
Chromosomal instability
Chromosomal instability can be described as increased gains or losses of
chromosomal material manifesting as aneuploidy, numeral changes of chro-
mosomes, or translocations, structural abnormalities (Sieber et al., 2003).
Chromosomal regions lost may contain tumor suppressor genes and gains
of regions may contain oncogenes giving the tumor cell a growth advan-
tage (Weinberg, 2007). Chromosomal aberrations caused by translocations
are seen in many malignancies, particularly in leukemias and lymphomas.
A typical example of this is the Philadelphia chromosome in myelogenous
leukemia. It is a nonrandom aberrant translocation between the ABL proto-
oncogene on chromosomes 9 and the BCR gene on chromosome 22. The
BCR-ABL gene encodes a protein with uncontrolled tyrosine kinase activ-
ity causing accelerated cell division (Nowell and Hungerford, 1960; Rowley,
1975; Kurzrock et al., 2003).
Loss of heterozygosity
Loss of heterozygosity (LOH), or loss of the normal, functional allele at a
heterozygous locus is regarded as chromosomal instability. LOH, leading
to increasing homozygosity, can be a consequence of a deletion, mitotic
recombination or non-disjunctional chromosome loss with or without redu-
plication, or it can be locus-restricted, caused by gene conversion or point
mutation, or epigenetic inactivation (Tischfield, 1997; Thiagalingam et al.,
2001) (Figure 1). LOH has been demonstrated to be the key mechanism
in inactivation of the tumor suppressor RB1 in retinoblastoma, the most
common intraocular tumor in childhood (Knudson, 1971). The frequency of
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LOH is observed to accumulate during tumor progression (Tamura, 2006).
LOH at the APC gene (5q21) is a frequent mechanism of gene inac-
tivation and is commonly seen in colorectal cancer. The APC gene is
an important component of the Wnt signal transduction pathway. Inacti-
vation of the APC gene leads to an inactive APC protein, which induces
stabilization of β-catenin, which is then shuttled to the nucleus, where it ac-
tivates transcription factors leading to expression of genes that induces cell
proliferation, and eventually carcinogenesis (Fodde, 2002; Nathke, 2004).
Germline mutations in APC are found in a majority of FAP patients (Gro-
den et al., 1991; Joslyn et al., 1991) and somatic mutations in more than
80% of sporadic colorectal cancer patients (Nagase and Nakamura, 1993;
Kinzler and Vogelstein, 1996). APC mutations are believed to occur in the
earliest stage of colorectal carcinogenesis (Powell et al., 1992; Vogelstein et
al., 1988). Mutations in APC alone are not sufficient for progression to
carcinoma; several more alterations in other tumor pathways are required
(Vogelstein and Kinzler, 2004) (see Figure 2).
Microsatellite instability
Microsatellite instability (MSI) arises when short nucleotide repeats are
expanded or shortened. The repeated sequences are usually 1 to 4 basepairs
in length and can be repeated up to 100 times. These repeats are scattered
widely throughout the genome and may occur in both coding and non-
coding regions and are hence also found in several human genes. MSI is
found in 15-25% of sporadic tumors and in over 90% of Lynch syndrome
tumors (Peltomaki, 2003; Aaltonen et al., 1993). Microsatellites are targets
of slippage of the DNA polymerase during replication, leading to variability
in length of the repeated sequence (Peltomaki, 2001). MSI can readily be
detected if many cells are affected by the same change, as an indicator of
clonal expansion (de la Chapelle, 2003). Recently, it has been possible to
amplify small amounts of DNA that equivalents to the amount of DNA
from a single cell to detect MSI in tumors. This means that tumors may
have MSI but due to small number of clones with unstable alleles it remains
undetected by conventional PCR (Coolbaugh-Murphy et al., 2004)
DNA mismatch repair
MSI has been studied extensively and it is caused by defects in the postrepli-
cation mismatch repair mechanism responsible for the fidelity of DNA repli-
cation (Jiricny, 1998). In humans, at least six different MMR genes (MLH1,
MSH2, MSH6, MLH3, PMS2 and MSH3 ) have been identified. The MMR
proteins interact with each other to form protein complexes that mediate
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Sporadic Hereditary
1. 2. 3. 4. 5.
Normal allele
Mutant allele (nucleotide alteration)
Epigenetic silencing of allele
B.A.
Figure 1: A. According to Knudson’s ’two hit’ theory, both copies in a tumor
suppressor need to be inactivated for a normal cell to transform into a tumor cell.
In hereditary cancer, a person has a germline mutation in one allele (the “first
hit”), and only a “second hit” is needed for tumorigenesis: whereas in sporadic
cancer the likelihood of both copies of the same gene becoming inactivated is
rare. B. Different mechanisms of second hit. 1. Mitotic non-disjunction where
the paternal chromosome is lost, 2. mitotic recombination or gene conversion,
the mutated locus replaces the normal locus, 3. deletion of the normal allele, 4.
sporadic mutation in paternal allele, 5. gene silencing by promoter methylation of
the wild-type allele (Modified from Aittomaki and Peltomaki, 2006).
distinct functions in repairing insertion/deletion and single-base substitu-
tion mismatches (Peltomaki, 2001). MLH1 protein together with PMS2 di-
rects the mismatch recognition complex to repair insertion-deletion loops,
whereas MSH2 together with MSH6 repair single-base mismatches (Pel-
tomaki, 2001; Chao and Lipkin, 2006). MMR proteins also participate in
additional mechanisms that could contribute to carcinogenesis, most no-
tably initiation of apoptosis in response to DNA damage (Fishel, 2001; Li,
1999).
MSI at microsatellites is estimated to be more than 100-1000 times
higher in MMR deficient cells compared to proficient cells (Parsons et al.,
1993). MSI is used to directly test whether MMR deficiency (a muta-
tor phenotype) is involved in specific tumor types. Almost all described
MLH1 /MSH2 mutations cause high degree of MSI (MSI-H) in tumors (Liu
et al., 1999; Lipkin et al., 2004). Currently it is thought that MMR gene
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mutations are recessive on a cellular level, and therefore, both alleles need
to be inactivated for the development of malignant phenotype.
2.3 Cancer epigenetics
Epigenetic changes are modifications in the DNA that are passed on to
the daughter cell during cell division that do not involve a change in DNA
sequence. DNA methylation involves the addition of a methyl group to
DNA at CpG sites. During the last decades it has become evident that DNA
methylation has an important role in regulation of oncogenes and tumor
suppressor genes by means of hypo- and hypermethylation, and loss of
imprinting (Feinberg, 2004). CpG islands are GC-rich regions that display
unmethylated CpG-nucleotides, and these CpG islands are predominantly
located in promoters, close to the transcription site (Esteller, 2008; Jones
and Laird, 1999; Antequera and Bird, 1993).
Epigenetic silencing (hypermethylation) of tumor suppressors and re-
activation (hypomethylation) of oncogenes contribute to cancer develop-
ment. Global genomic hypomethylation at CpG dinucleotides was the first
epigenetic abnormality identified in cancer cells (Christman et al., 1977;
Feinberg, 2004). Hypomethylation is observed to occur at an early stage
in colorectal neoplasia, leading to reactivation of genes critical for tumori-
genesis, which in normal cells are silenced by methylation (Feinberg et al.,
1988; Hernandez-Blazquez et al., 2000). Hypermethylation of promoter re-
gion CpG islands in turn has been observed to play an important role in
inactivation of tumor suppressor genes (Esteller et al., 2001; Costello et
al., 2000; Esteller, 2002; Herman and Baylin, 2003; Myohanen et al., 1998).
CIMP (CpG island methylator phenotype) was originally defined as methy-
lation at three or more of seven ”cancer-specific” loci (MINT1, MINT31,
p14 gene, p16 gene, THBS1, MLH1, and TIMP3 ) (Toyota et al., 1999).
A clear association has been described with family history and colorectal
cancer patients with CIMP (Rashid and Issa, 2004; Wynter et al., 2006;
Weisenberger et al., 2006; Frazier et al., 2003). As described in Figure 1,
epigenetic silencing is another mechanism for the “second hit” to inactivate
a tumor suppressor (Jones and Laird, 1999).
Hypermethylation of a gene in the germline, reflected in the presence
in somatic cells throughout the body, is known as germline epimutation.
Epimutations in MLH1 and MSH2 have been described as a possible mech-
anism for cancer susceptibility (Chan et al., 2006; Gazzoli et al., 2002;
Miyakura et al., 2004; Hitchins et al., 2007; Valle et al., 2007; Morak et al.,
2008).
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3 Hereditary colorectal cancer syndromes and
their molecular background
Colorectal cancer is one of the most common cancers world wide, and the
third most common cause of cancer-related death in the Western world
(Globcan 2002 database, International Agency for Research on Cancer,
www-dep.iarc.fr). It is mainly considered a disease of the elderly, as the
risk of colorectal cancer increases with age. In Finland roughly 2000 new
cases are diagnosed every year (Syo¨pa¨ja¨rjesto¨t, www.cancer.fi). A majority
of the cases are sporadic and believed to be due to environmental fac-
tors (Weitz et al., 2005), and around 20–25% of colorectal cancers occur
in individuals with positive family histories and therefore, are considered
to have an inherited susceptibility (de la Chapelle, 2004; Lynch and de la
Chapelle, 2003). About 5% of colorectal cancer with inherited predisposi-
tion is caused by highly penetrant mutations in single genes, giving rise to
hereditary syndromes that are mostly transmitted as autosomal dominant
traits. The two most common being, Lynch syndrome/HNPCC (heredi-
tary nonpolyposis colon cancer) which is caused by predisposing mutations
in the MMR genes, and FAP that is caused by mutations in the APC
gene. Other hereditary colorectal cancers are, MYH-associated polyposis,
Juvenile polyposis, Peutz-Jeghers, Bannayan-Ruvalcaba-Riley, and Cowden
syndrome (Abdel-Rahman and Peltomaki, 2004; de la Chapelle, 2004). Low
penetrance susceptibility genes, together with modifier genes and environ-
mental factors, account for a large share of inherited or sporadic colorectal
cancer (de la Chapelle, 2004).
Tumorigenesis is a multi-step process, where consecutive genetic alter-
ations drive the progressive transformation of normal cells into highly ma-
lignant cancer cells (Hanahan and Weinberg, 2000). Colorectal cancer is
probably the most studied cancer type. The studies on carcinogenesis of col-
orectal cancer through sequential accumulation of genetic alterations have
improved our understanding in cancer genetics and have provided useful
models also for other cancers. One reason for this is that colorectal cancers
occur, at least to some extent, through a well-known adenoma to carci-
noma sequence (Fearon and Vogelstein, 1990). Furthermore, biopsies from
different stages of colorectal cancer can be obtained relatively easily and
can thus be subjected to genetic analyses (de la Chapelle, 2004).
APC mutations, together with β-catenin activation, are believed to oc-
cur in the earliest stage, initiating the neoplastic process of colorectal car-
cinogenesis, and tumor progression results from mutations in other genes,
such as, KRAS and TP53 (Powell et al., 1992; Vogelstein et al., 1988;
Vogelstein and Kinzler, 2004) (Figure 2). KRAS indirectly regulates cell
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cycle progression by recruiting and activating proteins necessary for the
propagation of growth factor receptor signals. TP53 controls cell cycle
progression by activating DNA repair processes in case of DNA damage
and initiating apoptosis. KRAS mutations are observed to arise during the
adenoma stage, and mutations in TP53 and deletions on chromosome 18q
coincide with transition to malignancy. Mutations in KRAS and TP53 are
identified in approximately 50% of colorectal cancer (reviewed in Chung,
2000). Conversely, loss of chromosome 18q occurs later in the sequence of
development from adenoma to carcinoma. Loss of the 18q region is thought
to contribute to inactivation of the DCC tumor-suppressor gene, which is
reported to be mutated in approximately 70% of colorectal cancers (Fearon
and Vogelstein, 1990; Takayama et al., 2006).
Defective MMR leads to tumor development as a result of the accu-
mulation of widespread mutations within short repetitive sequences, in for
instance TGFβRII, and as well as other genes involved in signal transduc-
tion, DNA repair, transcriptional regulation, protein stability and immune
surveillance (Chao and Lipkin, 2006).
normal early adenoma
late 
adenoma carcinoma
APC /     
β-catenin KRAS
TP53 / 
18q (DCC)
MMR 
defect
TGFβRII, ACVR2, 
MRE11A, PTEN
Increased hypermethylation
Figure 2: Sequential genetic and epigenetic changes leading to colorectal tu-
morigenesis (modified from Kinzler and Vogelstein, 1996; Chung, 2000; Takayama,
2006; Kondo and Issa, 2004.
In the colon, aberrant DNA methylation arises early and contributes to
later stages of colon cancer formation and progression through CIMP. Most
colorectal cancers have epigenetic abnormalities, together with the genetic
changes such as TP53, KRAS and β-catenin mutations (Issa, 2000; Kondo
and Issa, 2004).
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3.1 Lynch syndrome
Genetic characteristics of Lynch syndrome
Lynch syndrome, or HNPCC, is among the most common hereditary can-
cers in man and is caused by germline mutations in MMR genes MLH1,
MSH2, MSH6 and PMS2 (Abdel-Rahman et al., 2006). A database has
been established for the known mutations in MLH1, MSH2 and MSH6
that are associated with Lynch syndrome (The International Society for
Gastrointestinal Hereditary Tumors (InSiGHT), Database for MMR mu-
tations: www.insight-group.org). Mutations in MLH1 and MSH2 account
for approximately 90% of all MMR gene mutations (de la Chapelle, 2004).
Some frequent mutations have been described in Lynch syndrome including
founder mutations inherited from a common ancestor. These can be tested
for as the first step in high-risk individuals from isolated populations (Pel-
tomaki and Vasen, 2004). However, among families clinically diagnosed
with Lynch syndrome, the proportion of MMR mutation varies consid-
erably between different studies, ranging from approximately 30% to 90%
(e.g., Lynch and de la Chapelle, 2003; Renkonen et al., 2003; Nystrom-Lahti
et al., 1996). In MMR mutation-negative families, the etiology remains to
date unknown, but possible explanations are certain complex structural
alterations (e.g., inversions) (Wagner et al., 2002) as well as regulatory
changes in non-coding regions (Shin et al., 2002). MSI is used to directly
test whether MMR deficiency (a mutator phenotype) is involved in specific
tumor types.
Although all cells in Lynch syndrome patients carry a MMR gene mu-
tation (“first hit”), tumor development additionally requires somatic inac-
tivation of the remaining wild-type allele (“second hit”) in a target tissue.
Germline mutation in MMR gene leads to accumulation of replication er-
rors, mainly at short repetitive DNA sequences in the tumor cells, and gives
rise to the molecular hallmark of Lynch syndrome, MSI. MSI contributes to
cancer via an increased mutation rate in both microsatellites and in genes
important in cancer suppression. The revised Bethesda guidelines (Table 2)
are used for identification of individuals with Lynch syndrome who should
be tested for microsatellite instability (Umar et al., 2004a). MSI is present
in 15-25% of corresponding sporadic tumors as well (Peltomaki, 2003).
Clinical characteristics and tumor spectrum of Lynch syndrome
When Lynch syndrome was first described, it was considered a familial syn-
drome characterized by an increased incidence of colorectal and endometrial
cancer. At present there is disagreement on defining which other tumors
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Figure 3: Organs affected in Lynch syndrome. Tumors associated with Lynch
syndrome are: tumors of colon and rectum, endometrium, cancer of the stom-
ach, ovary, ureter/renal pelvis, brain, small bowel, hepatobiliary tract, and skin
(sebaceous tumors).
belong to Lynch syndrome. However, tumors that have sufficiently high rel-
ative risk compared to the general population are to be considered Lynch
syndrome tumors (Watson and Riley, 2005). Therefore, the term hereditary
nonpolyposis colorectal cancer may be too restrictive, and Lynch syndrome
has been proposed as a more appropriate name to cover this syndrome
(Umar et al., 2004a). Epidemiological studies have found that tumors of
colon and rectum, endometrium, stomach, ovary, ureter/renal pelvis, brain,
small bowel, hepatobiliary tract, and skin (sebaceous tumors) are associ-
ated with Lynch syndrome (Vasen et al., 1999; Aarnio et al., 1999). Of
these, cancers of the colon and rectum, endometrium, ureter, renal pelvis,
and small bowel have the highest relative risk compared to the average
population, and are, therefore, the most specific for Lynch syndrome.
Uniform clinical criteria were needed to provide consistency in collabo-
rative studies. For this purpose the Amsterdam criteria were developed in
1991, before the genetic basis of the disorder was known (Vasen et al., 1991).
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Amsterdam criteria I were found to be too stringent as the importance of
extracolonic cancers became clear and thus the ’Amsterdam criteria II’ were
developed in 1998 (Table 2) (Vasen et al., 1999). Whereas the definition
of Lynch syndrome tumor spectrum remains controversial, the consensus
is that at least cancers of the colon and rectum, endometrium, small in-
testine, ureter and renal pelvis (Figure 3) are associated with sufficiently
high relative risk compared with the average population to justify their
inclusion in the clinical consensus criteria for the syndrome (Amsterdam
criteria II; Vasen et al., 1999). The diagnosis of Lynch syndrome is made
by considering the family history using Amsterdam criteria and when the
mutation in the family is known, genetic testing can be used for diagnosis.
The Bethesda guidelines were introduced in 1996 to help aid in the decision
process for whether individuals with cancer in families that do not fulfill
Amsterdam criteria should undergo genetic testing (Rodriguez-Bigas et al.,
1997). The revised Bethesda guidelines were developed for several rea-
sons: to identify patients who were at risk for hereditary cancer, to include
a complete spectrum of colonic and extracolonic cancers, and to identify
MSH2 and MLH1 germline-mutation carriers in patients with cancers who
might or might not fulfill the Amsterdam II criteria (Umar et al., 2004a).
The International Workshop developed the Bethesda panel of five mono-
and dinucleotide markers to determine MSI status in tumors. Tumors with
two or more unstable markers are considered to have high frequency of MSI
(MSI-H), whereas those with no unstable markers were microsatellite stable
(MSS) (Boland et al., 1998; Umar et al., 2004a).
The average age of onset of colorectal cancer from Lynch syndrome
patients is about 45 years, whereas in sporadic cancers it is 20 years later
(Lynch and de la Chapelle, 1999; Peltomaki et al., 2001). The tumors
are mainly located in the proximal colon, and multiple synchronous and
metachronous tumors are common (Jarvinen et al., 2000). Lynch syndrome
is also characterized by frequent occurrence of extracolonic tumors, mainly
in the endometrium (Aarnio et al., 1999). The risk of colorectal cancer in
MMR gene mutation carriers is estimated to be around 80% by the age of
70, the risk being slightly higher in males than females. The lifetime risk
of endometrial cancer in predisposed females is 42% in MLH1 mutation
carriers and 61% for MSH2 mutation carriers (Aarnio et al., 1999; Vasen
et al., 1996). The risk of other extracolonic, extraendometrial cancers is
estimated to be approximately 2 to 10% (Aarnio et al., 1999; Watson and
Lynch, 2001) (Table 3).
The risk of extracolonic cancers in Lynch syndrome has been found to
be higher in MSH2 mutation carriers than MLH1 mutation carriers (Vasen
et al., 2001; Watson et al., 2008), but the correlation between germline
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Table 2: The clinical consensus criteria for diagnosis of Lynch syndrome (Vasen
et al., 1991; Vasen et al., 1999)
Amsterdam Criteria I and II: Revised Bethesda guidelines
1. At least three relatives with Lynch
syndrome associated cancer (in col-
orectum, endometrium, small bowel,
ureter and renal pelvis)
2. One should be a first degree rela-
tive of the other two
3. At least two successive affected
generations
4. At least one Lynch syndrome-
associated cancer diagnosed under 50
years
5. FAP should be excluded
6. Tumors should be verified by
pathological examination
1. Colorectal cancer diagnosed in a
patient before 50 years of age
2. Presence of synchronous,
metachronous colorectal, or other
Lynch syndrome-associated tumors,
regardless of age
3. Colorectal cancer with the MSI-H
histology diagnosed in a patient be-
fore 60 years of age
4. Colorectal cancer diagnosed in one
or more first-degree relatives with
an Lynch syndrome-associated tu-
mor, with one of the cancers diag-
nosed before age 50
5. Colorectal cancer diagnosed in two
or more first- or second-degree rel-
atives with Lynch syndrome associ-
ated tumors, regardless of age
Table 3: The cumulative incidence of Lynch syndrome associated tumors by age
70 (Aarnio et al., 1999)
Site of Tumor Finnish population (%) Lynch syndrome families (%)
Colon and rectum 1.6 82
Endometrium 1.3* 60*
Stomach 0.8 13
Ovary 1.3* 12*
Bladder, ureter
and urethra 0.7 4.0
Brain 0.9 3.7
Kidney 0.8 3.3
Biliary tract,
gallbladder 0.2 2.0
*Women only
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mutation and clinical phenotype is generally poor in the case of Lynch
syndrome. It has also been shown that MSH6 mutations are associated
with families with a higher incidence of endometrial carcinoma (Wijnen et
al., 1999).
The cancer spectrum also varies between Lynch syndrome families ge-
ographically, which is partly due to different environmental factors. For
example, it is well-known that Asian families generally have a higher inci-
dence of stomach cancer compared to Western countries, where colorectal
cancer predominates (Cai et al., 2003; Lynch et al., 1988a; Lynch et al.,
1988b; Lynch et al., 1998). For this reason, these countries have devel-
oped modified diagnostic criteria in addition to the Bethesda guidelines
(reviewed in Umar et al., 2004b; Lee et al., 2005; Liu et al., 2004; Zhang et
al., 2005).
An approximately four-fold increased incidence of brain tumors, mainly
gliomas, has been reported in Lynch syndrome families (Vasen et al., 1996;
Vasen et al., 1996; Aarnio et al., 1999). Colon cancer and concurrent ma-
lignant glioma/glioblastoma have been reported to occur in the Lynch syn-
drome variant of Turcot syndrome, in association with mutations in MLH1,
MSH2, PMS2, or MSH6 (Hamilton et al., 1995; Chan et al., 1999; De Rosa
et al., 2000; Hegde et al., 2005). Colon polyposis and medulloblastoma are
associated with heterozygous APC gene mutations in the FAP variant of
Turcot syndrome (Mori et al., 1994).
Muir-Torre syndrome is a rare subtype of Lynch syndrome, and in ad-
dition to the Lynch syndrome tumor spectrum, patients also display skin
tumors, mainly sebaceous gland tumors or keratoacanthomas (Cohen et al.,
1995; Schwartz et al., 1989). Muir-Torre tumors display MMR defects with
accompanying MSI (Kruse and Ruzicka, 2004).
4 Tissue specificity in hereditary cancer syndromes
A feature that all hereditary forms of cancer have in common is that they
predispose to only certain types of tumors. However, the genes responsible
for the syndrome are usually expressed in all tissues and regulate fairly
universal processes like DNA repair and cell cycle control (Chao and Lipkin,
2006). Apart from Lynch syndrome, there are other hereditary cancer
syndromes that predispose to specific types of cancer, such as Li-Fraumeni,
Von Hippel-Lindau, and multiple endocrine neoplasia 2 that are well-known
hereditary cancer syndromes. Li-Fraumeni syndrome is a rare autosomal
dominant syndrome characterized by early-onset tumors including bone and
soft tissue sarcomas, breast cancer, brain cancer, leukemia and childhood
adrenocortical tumors (Li and Fraumeni, 1969). Germline mutations in
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the tumor suppressor gene p53 account for the majority of Li-Fraumeni
syndrome families (Varley, 2003). Von Hippel-Lindau syndrome is caused
by germline mutations of the VHL tumor suppressor gene (Latif et al., 1993;
Stolle et al., 1998). It is an autosomal dominant trait distinguished by renal
cell carcinoma, hemangioblastoma, and pheochromocytoma (Maher et al.,
1991). Germline mutations in the RET proto-oncogene are associated with
multiple endocrine neoplasia type 2, which is characterized by medullary
thyroid carcinoma, pheochromocytoma (both of neural crest origin), and
parathyroid hyperplasia (Eng et al., 1996).
Eng and Ponder (1993) discussed several explanations for the tissue
specificity of cancer occurrence although the mutation in the cancer sus-
ceptibility genes occurs in the germline, and is thus, being present in all
tissues of the body. In some cases it may be explained by common origin
of cells but often the underlying mechanism is more complex. The variable
expression and penetrance of phenotypes may be modulated by different
germline mutations within the susceptibility gene, mutations causing tar-
get protein conformational change, or modulation of expression by modifier
genes (Ribeiro et al., 2001; Eng and Ponder, 1993).
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4.1 Tissue specificity & MMR defect
There are several separate mechanisms that contribute to tissue specificity
in MMR deficient cells but they contribute in different ways in different
tissues (reviewed in Chao and Lipkin, 2006). Because mutation rates are
significantly higher in MMR defective versus proficient cells, it is thought
that the cell types with the highest overall proliferation rate (and there-
fore the highest total number of genomic replication cycles) would be most
susceptible to cancer due to MMR deficiency (Parsons et al., 1993). This
is believed to be the case in the gastrointestinal epithelium, having the
highest known proliferation rate of all cell types (Lipkin, 1973). In the
gastrointestinal and genitourinary epithelium, exposure to mutagens in the
diet and concentration of environmental mutagens in the urine has been as-
sociated with carcinogenesis (Watson et al., 2004; Lynch and Smyrk, 1998).
Helicobacter pylori infection has also been shown to be related to gastric
carcinoma (Lynch et al., 2005).
Since MMR defects particularly affect genes which contain short repet-
itive sequences, the dependence of these genes in different organs has been
suggested to be critical for cancer development due to MSI (Schwartz et al.,
1999; Yamamoto et al., 2000; Duval et al., 2002). For instance, TGFβRII
and ACVR2, sharing common regulatory mechanisms (Deacu et al., 2004),
are frequently mutated in colorectal tumors, causing frameshift mutations
(Markowitz et al., 1995; Mori et al., 2002; Mori et al., 2001). Several other
genes with presumed tumor suppressor functions and containing coding
microsatellites have been shown to be mutated at various frequencies in
both sporadic MSI-H and Lynch syndrome associated colorectal, gastric
and endometrial cancers. These include additional genes such as IGFIIR,
PTEN (Kuismanen et al., 2002; Souza et al., 1996) involved in signal trans-
duction, MSH3, MSH6, MBD4, BLM, MRE11 important for DNA repair
(Abdel-Rahman et al., 2008; Baranovskaya et al., 2001; Malkhosyan et al.,
1996), as well as genes that play roles in transcriptional regulation, protein
stability and immune surveillance.
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AIMS OF STUDY
This study was conducted to elucidate the genetic background and tissue
specificity of MMR deficient tumors from Lynch syndrome families. The
specific aims were:
1. To investigate the frequency and nature of inactivation of the wild-
type allele in tumors from MMR gene germline mutation carriers
(I-IV)
2. To examine the mechanisms of cancer predisposition in Lynch syn-
drome patients by determining the molecular profiles for different tu-
mors from a nationwide cohort of Lynch syndrome families, including
tumors of brain, urinary tract, stomach, colorectum and endometrium
(II, III)
3. To study the role of large genomic rearrangements and germline epi-
mutations in MMR genes in mutation-negative patients with sus-
pected Lynch syndrome (IV)
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MATERIALS & METHODS
For detailed information on materials and methods used in the present
study, please refer to the Materials and Methods section of each paper.
1 Patients & samples
The material for studies I-IV were selected from the Hereditary Colorec-
tal Cancer Registry of Finland that includes 194 verified Lynch syndrome
families classified according to the Amsterdam criteria (Vasen et al., 1999;
Vasen et al., 1991) or revised Bethesda guidelines (Umar et al., 2004a), in
which a germline change in the MMR genes has been detected by exon-
specific screening methods in 148 families. A sample cohort consisting of 7
Finnish Lynch syndrome patients and 16 Swiss putative Lynch syndrome
patients were studied to determine proportion of genomic rearrangements
and to study LOH as a second somatic hit in Lynch syndrome (publication
I).
MMR gene mutation carriers (n=15) with gastric cancer were selected
in order to study whether gastric cancer is a true Lynch syndrome associ-
ated malignancy (publication II). The Lynch syndrome associated gastric
cancers were compared to sporadic gastric carcinomas (n=46). Sporadic
gastric cancers were initially divided into three different subgroups based
on histology and MSI status: intestinal MSI (n=10), intestinal MSS (n=20)
and diffuse MSS (n=16).
All available brain tumor samples (n=7) and urological tumor sam-
ples (n=14) (publication III) from patients belonging to verified Finnish
Lynch syndrome families were selected. The urinary tract tumors included
4 renal cell adenocarcinomas and 10 uroepithelial cancers (5 ureter and 5
urinary bladder). All tumor samples had corresponding normal tissue when
available. Colorectal carcinoma samples (n=48) and endometrial carcinoma
samples (n=60) from well-characterized Lynch syndrome families, all fulfill-
ing the Amsterdam and Bethesda criteria, were selected in order to compare
findings in brain and urological tumors from Lynch syndrome families.
Lynch syndrome MMR mutation carriers with colorectal cancer and
endometrial cancer (n=51) were also chosen to make clinical comparisons
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with putative Lynch syndrome families lacking germline mutations in MMR
genes by conventional screening (Holmberg et al., 1998; Renkonen et al.,
2003) but displaying loss of MLH1, MSH2 or MSH6 expression in tumor
tissue (n=45, publication IV). Among the original 81 kindreds ascertained
through family history suggestive of Lynch syndrome, 11 families showed
no detectable germline changes, despite aberrant MMR protein expression
and MSI in tumor tissue. A diagnostic cohort of 34 patients with suspected
Lynch syndrome was included, displaying loss or MMR protein expression,
in whom no MMR gene mutations have been found by conventional methods
(publication IV).
Formalin-fixed paraffin-embedded and fresh frozen specimens of tumor
and matching normal tissues were collected from the pathology departments
of different hospitals in Finland for all the studies. Representative areas
of the paraffin-embedded tissue from both the cancerous and normal areas
were selected for immunohistochemistry and DNA extraction. DNA was
prepared from archival tissue samples according to the method of Isola et
al. (1994). DNA was extracted from lymphocytes and lymphoblasts as
described in (Lahiri and Nurnberger, 1991).
Informed consent was obtained from patients participating in this study,
and the appropriate institutional review boards approved this study.
2 Protein expression analyses & histology
2.1 Immunohistochemistry (I-IV)
Immunohistochemistry was used to confirm the presence or absence of
MMR proteins, β-catenin and p53 in tumor tissue. Immunohistochemi-
cal results for the MMR proteins were interpreted using nuclear staining of
normal tissue and stromal cells included in each tumor section as a reference
for the evaluation of the staining results. β-catenin expression was consid-
ered aberrant if there was nuclear staining in more than 10% (not observed
in the matching normal tissue). In reporting p53 protein stabilization, a
cut-off level of more than 10% positive tumor cells was used.
2.2 Helicobacter pylori status & tumor grading (II, III)
Gastric carcinomas were classified according to Laure´n (1965) into intesti-
nal and diffuse types of tumors, and the differentiation grade was deter-
mined according to the WHO classification (Fenoglio-Preiser et al., 2000).
Chronic gastritis, atrophy, intestinal metaplasia and H. pylori infection
were evaluated and graded according to the Sydney classification (Dixon et
al., 1996). H. pylori status was verified using hematoxylin and eosin and
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Table 4: Methods used in this study (I-IV)
Study
METHOD I II III IV
1. DNA extraction x x x x
2. Protein expression/histology
2.1 Immunohistochemistry
MLH1, MSH2, MSH6 x x x x
p53, β-catenin x x
2.2 Histology and H. pylori status x
3. Mutation analysis
3.1 Exon-specific sequencing
MLH1, MSH2, MSH6 x x x x
KRAS, BRAF, CTNNB1 x x
3.2 SSCP
KRAS, BRAF, CTNNB1 x x
4. MSI analysis
4.1 (BAT25, BAT26, D2S123, D5S346, D17S250) x x x x
4.2 Small-pool PCR x
4.3 Frameshift-prone target genes
ACVR2, MRE11A, PTEN x x
MBD4, BLM, TGFβRII x
5. LOH analysis
5.1 MLPA (deletion MLH1 ex16, MSH2 ex3-5) x x x x
5.2 SNuPE (MLH1, APC ) x x
5.3 APC microsatellite markers (D5S346, D5S1965) x x
5.3 MSH2 microsatellite markers (D2S2378, CA7, D2S123) x
6. Methylation analysis
6.1 MS-MLPA x x x
6.2 Bisulfite modification & sequencing x
6.3 MSP x
7. Deletion detection
7.1 MLPA x x x x
7.2 Long-Range genomic PCR x
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Alcian-blue/periodic acid Schiff stains added with modified Giemsa. Can-
cers of the bladder and ureter were of transitiocellular type, and graded
according to the WHO. Kidney tumors were adenocarcinomas and graded
using Fuhrman (1982). Brain tumors were graded according to the most
commonly used classification system for brain tumors developed by the
WHO.
3 Mutation detection analysis
3.1 Exon-specific sequencing (I-IV)
Immunohistochemistry was first performed on tumor tissue to identify the
affected MMR gene. After the deficient MMR gene was identified, the
respective MMR genes were screened for point mutations using DNA am-
plification, genomic sequencing, and specific testing for the founder muta-
tion, as described previously (Chadwick et al., 2001; Vahteristo et al., 2001;
Nystrom-Lahti et al., 1995).
3.2 Single strand conformation polymorphism (II, III)
KRAS, BRAF, and CTNNB1 were initially screened for hot spot muta-
tions (Deng et al., 2004; Abdel-Rahman et al., 2005; publication II) by sin-
gle strand conformation polymorphism (SSCP) analysis of genomic DNA.
Samples screened with SSCP were first PCR amplified and then separated
on a polyacrylamide gel with 1 x MDE Gel Solution (Cambrex Bio Sci-
ence Rockland Inc., Rockland, ME) to improve sensitivity to conforma-
tional changes. For detection of DNA, gels were stained using silver nitrate.
Changes observed on the SSCP gels were then sequenced to determine the
exact nucleotide changes.
4 Microsatellite instability analyses
4.1 Bethesda panel for studying MSI (I-IV)
The Bethesda panel (Boland et al., 1998; Umar et al., 2004a) of five mono-
and dinucleotide markers was used to determine MSI status in tumors since
it is the hallmark of MMR deficiency and recommended by the International
Workshop (Boland et al., 1998). The microsatellite markers were run on an
ABI 3730 automatic DNA sequencer and analyzed with GeneMapper 4.0
software (both Applied Biosystems, Foster City, CA). Tumors with two or
more unstable markers were considered to have MSI-H, whereas those with
no unstable markers were MSS.
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4.2 Small-pool PCR (III)
Small-pool PCR (SP-PCR) is a sensitive method for detection and quantifi-
cation of MSI in somatic cells (Coolbaugh-Murphy et al., 2004). SP-PCR
was conducted on all brain tumor samples and their matching blood sam-
ples. The fluorescently labeled dinucleotide markers D5S346 and D2S123
(Boland et al., 1998) were studied using SP-PCR to genotype individual al-
leles. The small-pool PCR reactions were essentially performed as described
earlier (Coolbaugh-Murphy et al., 2004), in a 25µl reaction volume and 39
parallel aliquots per sample, using Expand High Fidelity PCR System En-
zyme Mix (Roche, Mannheim, Germany) and 50 pg of DNA template. The
annealing temperature was 62◦C. From each aliquot (clone), 0–4 alleles am-
plified, of which those that deviated more than 1 bp from the constitutional
allele size (determined by standard PCR) were considered unstable.
The average total number of alleles analyzed per tumor specimen was
15 and 34 for D2S123 and D5S346, respectively, and 40 and 64 per blood
specimen. Mutation frequency was calculated by dividing the number of
alleles with MSI by the total number of alleles in each sample.
Mutation frequency =
No. alleles with MSI
Total no. of alleles
4.3 Mononucleotide repeats (II, III)
Eight mononucleotide repeats in six frameshift-prone target genes were
PCR amplified and the products were run on an automated capillary elec-
trophoresis sequencer and analyzed with the GeneMapper 4.0 program (Ap-
plied Biosystems, Foster City, CA).
5 Loss of heterozygosity analysis
5.1 Multiplex ligation-dependent probe amplification (I-IV)
Multiplex ligation-dependent probe amplification (MLPA) (MRC Holland,
Amsterdam, the Netherlands) was used to detect locus restricted LOH in
cases with verified MMR germline mutation. Two kits, SALSA MLPA P003
and P008, were used. SALSA MLPA kit P003 has probes for all exons of
MLH1 and MSH2 as well as 7 control probes mapping to different chro-
mosomes. SALSA MLPA kit P008 has probes for all exons of MSH6 as
well as for 13 of the 15 PMS2 exons; in addition there are probes for MU-
TYH (MYH ), MLH3, MSH3 and a probe for APC. All reactions were done
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following the manufacturer’s instructions (http://www.mrc-holland.com;
Schouten et al., 2002). The principle of MLPA is as follows: each MLPA
probe pair consists of two target sequence specific oligonucleotides that can
be ligated to each other when hybridized to a target sequence. All lig-
ated probes have identical sequences at their 5’ and 3’ ends (a universal
PCR primer sequence), enabling simultaneous amplification using only one
primer pair in a PCR reaction. Furthermore, for every probe pair, one of
the probes also contains a stuffer sequence, giving the fragments produced
unique sizes ranging from 130 to 480 bp (see Figure 4A for outline).
In brief, the DNA is first denatured and fragmented after which the
MLPA probes are hybridized to their target sequences overnight. If no
deletion is present, the probes can hybridize to their target sequences and
will, after addition of ligase, be ligated. Only ligated probes are amplified
in the PCR reaction. One PCR primer is fluorescently labeled, producing
a PCR product that was run on an automated sequencer and analyzed
with GeneMapper software (version 4.0, Applied Biosystems, Foster City,
CA). Each probe produces a product of a unique size that can be detected
using GeneMapper software. The whole reaction of more than 40 probes is
visualized as a peak diagram (Figure 4B).
Relative peak values were calculated for each sample by dividing the
peak area of a given probe pair (Px) by the sum of the peak areas of all
probes in that sample (Pall). This value was then divided by the mean rel-
ative peak value of normal DNAs from healthy controls, to obtain a dosage
ratio (D). To calculate LOH, the dosage ratio of a patient’s tumor sample
was divided with the patient’s normal sample. Forty percent reduction in
fluorescence intensity was indication of loss of heterozygosity.
D =
sample Px/Pall
control Px/Pall
5.2 Single nucleotide primer extension (II, III, IV)
The extension reaction of single nucleotide primer extension (SNuPE) is
based on the incorporation of a single dideoxy nucleotide that is selected to
produce differential extension of a primer annealed close to the polymorphic
site. In MLH1 associated cases, LOH was determined using the I219V A/G
polymorphism (Renkonen et al., 2003; Ollikainen et al., 2007). The APC
gene was examined by utilizing a coding polymorphism C/T at nucleotide
1458 (Renkonen et al., 2005). LOH ratios (L) of allelic peak areas (A1 for
allele 1, A2 for allele 2) in normal relative to tumor were calculated, and
values at or below 0.6 or above 1.67 (indicating that the transcript of one
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PCR primer sequence Y PCR primer sequence X
Each probe pairhybridizes to theirtarget sequences
The two parts ofhybridized probe areligated by a thermostableligase
All ligation products are amplified by PCR using only one primer pair.
The amplification product ofeach probe has a uniquelength (130-480 bp)
Stuffer
sequence
3'     Target A       5'
3'     Target B       5'
3'     Target A       5' 3'     Target B       5'
5' Y
X X
XX
X XYY
Y Y
Y
5' 5'
5' 5'
3' 3'
5'
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sequence
Hybridization
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B
Figure 4: Outline of the MLPA reaction (modified from Schouten et al., 2002).
The principle of the MLPA method (A.) and an example of a peak diagram (B.).
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allele had decreased 40% or more) were considered strict LOH (Ollikainen
et al., 2005) and ratios between 0.61-0.75 and 1.66-1.33 were considered
putative LOH (Cleton-Jansen et al., 2001). SNuPE was also applied when
performing allele-specific expression analysis on MLH1 in study IV.
L =
tumor A1/A2
normal A1/A2
5.3 Microsatellite markers in detecting LOH (II, III)
In MSH2 or MSH6 mutation carriers, LOH was analyzed using flanking mi-
crosatellite markers, D2S2378, CA7 and D2S123 (Ollikainen et al., 2005). In
addition to SNuPE, microsatellite markers next to the APC gene, D5S1965
(200 kb upstream of APC ) and D5S346 (<100 kb downstream of APC ),
were also used to study LOH of APC (Renkonen et al., 2005). LOH was
calculated as described above (section 5.2) comparing peak areas of normal
relative to tumor, using the same ratios for putative and strict LOH.
6 Methylation detection
6.1 Methylation-specific MLPA (II-IV)
The methylation-specific MLPA (MS-MLPA) (MRC Holland, Amsterdam,
the Netherlands) was used to detect methylation in MMR gene promoter
regions using probes that contain one or two digestion sites for the methy-
lation-sensitive HhaI enzyme. The kit ME011 (32 probes) includes five
probe pairs for MLH1, three probe pairs for MSH2, and three probe pairs
for MSH6, as well as ten probes for MLH3, PMS2, MSH3 and MGMT. In
addition, the kit contains 11 different control probes that do not have HhaI
enzyme digestion site. The ME001B kit (41 probes), on the other hand,
contains probes for 24 different tumor suppressor genes, including two probe
pairs for MLH1. The present tumor suppressor genes were selected because
their inactivation has been found to be important in a wide variety of
human cancers (Verma and Srivastava, 2002; Laird, 2003). Furthermore,
the genes included were found relevant in relation to the tumors analyzed
in the present study either through their role in DNA repair, apoptosis or
cell cycle regulation. Table 5 includes detailed information on all 24 tumor
suppressor genes included in the ME001B kit. The kit includes another 15
probes that function as control probes because they lack an HhaI digestion
site. Normal DNA specimens derived from lymphocytes of healthy controls
were included as controls in every assay.
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Table 5: All tumor suppressor genes included in the MS-MLPA ME001B kit
(modified from Joensuu et al., 2008)
Gene symbol Protein function
APC Participates in Wnt signaling, free beta-catenin level reg-
ulator, involved in cell adhesion and active cell migration
ATM Protein kinase, DNA damage sensor and damage rea-
sponse regulator, checkpoint signaling activator at dou-
ble strand breaks, apoptosis and genotoxic stresses, in-
volved in signal transduction and cell cycle control
BRCA1 Central role in DNA repair by facilitating cellular re-
sponse to DNA repair, mediator of E2-dependent ubiq-
uitination, lipid synthesis inhibitor
BRCA2 Involved in double-strand break repair and/or homolo-
gous recombination
CASP8 Protease in the activation cascade of caspases responsible
for apoptosis
CD44 Receptor for hyaluronic acid, mediator of cell-cell and
cell-matrix interactions, role in cell migration, tumor
growth and progression
CDH13 Calcium dependent cell adhesion protein
CDKN1B Involved in cell cycle arrest, cellular response to DNA
damage, regulator of cell cycle, effector of signal trans-
duction pathways that control cell differentiation
CDKN2A
(encoding p14ARF)
Induces cell cycle arrest in G1 and G2 phases, negative
regulator of the proliferation of normal cells
CDKN2B Regulator of cell cycle, passage through the G1 check-
point, tightly linked and highly homolog to CDKN2A
CHFR E3 ubiquitin-protein ligase, cell arrest in early prophase
DAPK1 Calcium/calmodulin-dependent serine/threonine kinase,
positive regulator of apoptosis
ESR1 Nuclear estrogen receptor α, involved in gene expression
regulation, cellular proliferation and differentiation
FHIT Diadenosine 5’,5”’-P1,P3-triphosphate hydrolase, in-
volved in purine metabolism
GSTP1 Involved in conjugation of reduced glutathione to a wide
number of exogenous and endogenous hydrophobic elec-
trophiles
HIC1 Transcriptional repressor
IGSF4 (=CADM1 ) Cell adhesion molecule
MLH1 DNA mismatch repair protein
PTEN Protein and lipid phosphatase, cell cycle progression and
cell survival modulator
RARB Receptor for retinoic acid, gene expression regulator
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Table 5: cont. All tumor suppressor genes included in the MS-MLPA ME001B
kit (modified from Joensuu et al., 2008)
Gene symbol Protein function
RASSF1(A) Required for death receptor- dependent apoptosis Iso-
form A inhibits proliferation by negatively regulating cell
cycle progression
TIMP3 Metalloproteinase inhibitor
TP73 Involved in apoptotic response to DNA damage
VHL Transcriptional repressor, ubiquitin conjugating protein,
cell cycle regulator
ATM, ataxia telangiectasia mutated; BRCA1, breast cancer type 1 susceptibil-
ity protein; BRCA2, breast cancer type 2 susceptibility protein; CASP8, cas-
pase 8, apoptosis-related cysteine peptidase; CDH13, cadherin 13, H-cadherin;
CDKN1B, cyclin-dependent kinase inhibitor 1B; CDKN2B, cyclin-dependent
kinase inhibitor 2B; CHFR, checkpoint protein with forkhead and RING fin-
ger domains; DAPK1, death-associated protein kinase 1; FHIT, fragile his-
tidine triad gene; HIC1, hypermethylated in cancer 1; IGSF4 (=CADM1),
immunoglobulin superfamily, member 4; RARB, retinoic acid receptor beta;
TP73, cellular tumor antigen p73.
As in ordinary MLPA reactions, the MS-MLPA protocol starts with
DNA denaturation and overnight hybridization of probes complementary
to their specific DNA targets. The reaction is then divided into two parts.
One set is processed as a standard MLPA reaction, described in section 5.1
providing information on copy number changes. The other set of the MS-
MLPA hybridization reaction is incubated with the methylation sensitive
HhaI endonuclease and simultaneously the hybridized probes are ligated.
A sample that is not methylated is digested by the HhaI enzyme, while
methylated samples are not digested and therefore, are ligated. Digested
probes will not be amplified by PCR and hence will not generate a signal
when analyzed by capillary electrophoresis. In contrast, if the sample DNA
is methylated, the methylation of DNA prevents the DNA from being di-
gested, and will generate a signal. The MS-MLPA reaction outline is shown
below (Figure 5).
DM =
digested Px/Pctrl
undigested Px/Pctrl
The methylation dosage ratio (DM) was calculated by dividing the peak
area of a given probe (Px) by the sum of all peak areas of probes lacking a
digestion site (Pctrl). The ratio of Px to Pctrl of HhaI digested sample is
then divided by the ratio of an undigested sample (above).
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Probe design
Denaturation andprobe hybridization
Simultaneously Ligation and Digestion withmethylation sensitive HhaI enzyme
PCR amplification usingonly one universal primer pair
Fragment Analysis
Unmethylated Target 2Methylated Target 1
Only ligated probes are
exponentially amplified
Target specific sequence Primer YStuffer sequence
Target 1 Target 2
Primer X
1A 1B
2A 2B
1A 1B 2A 2B
M
M
M
M
Y 3''X5'
Figure 5: Outline of the MS-MLPA method (modified from Nygren, et al., 2005)
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Based on our titration experiments with genes known to have methyla-
tion or complete lack of methylation, a dosage ratio of 0.15 (corresponding
to 15% of methylated DNA) was regarded to indicate promoter methyla-
tion. This threshold value also provided the best discrimination of tumor
DNA relative to paired normal DNA where no methylation was generally
expected. The MS-MLPA technique was also independently validated by
another method, methylation-specific PCR.
6.2 Bisulphite modification and sequencing (IV)
DNA was modified using the CpGenome DNA Modification Kit (Chemicon,
Temecula, CA). For methylation analysis of the MLH1 promoter region, a
fragment from -370 to -49 relative to the initiating ATG was amplified from
bisulphite-modified DNA using methylation-unbiased primers MLH1 DEG
5’ and MLH1 DEG 3’ from Suter et al. (2004). Patient F36 displayed
a deletion of exons 1–2 and flanking areas, and hence the methylation
unbiased primers only amplified the wild-type allele. For analysis of the
deletion-containing allele, the MLH1 DEG 5’ primer was combined with a
methylation-unbiased reverse primer (study IV) from intron 2 beyond the
deletion. The PCR products obtained with methylation-unbiased primers
were sequenced to determine the methylation status.
To examine allele-specificity of methylation, bisulphite-converted DNA
amplified with primers MLH1 DEG 5’ and MLH1 DEG 3’ was first cloned
into a pCR2.1-TOPO vector using the TOPO TA Cloning System (Invit-
rogen, Carlsbad, CA), followed by sequencing of the cloned DNA.
For methylation analysis of the MSH2 promoter, a region from -651 to
-42 relative to ATG site was evaluated in two overlapping PCR fragments,
using methylation-unbiased primers NP1-F and NP1-R, from Chan et al.
(2006) for the area distal to initiating ATG, as well as a forward and a
reverse primer for the area proximal to initiating ATG (see study IV).
6.3 Methylation-specific PCR (IV)
Methylation-specific PCR (MSP) was performed using HotStarTaq DNA
polymerase (Qiagen, Valencia, CA) and bisulphite modified DNA. The
manufacturer’s standard protocol was applied to designing PCR conditions
for HotStarTaq polymerase. Primers from Kim et al. (2006) were used for
methylation analysis of the MLH1 promoter. Primers for the methylated
reaction (M) covered a region from -269 to -206 and those for the un-
methylated reaction (U) a region from -288 to -192 relative to the initiating
ATG. PCR products were visualized on an agarose gel with UV transil-
lumination. The RKO cell line with verified MLH1 promoter methylation
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and lymphocyte-derived DNA from a healthy control served as positive and
negative controls, respectively.
7 Deletion detection
7.1 MLPA (I-IV)
MLPA, described in section 5.1, was also used to screen DNA samples for
large genomic rearrangements in all exons of the MMR genes in cases in
which no mutations in the MMR genes had been found, despite lack of
MLH1, MSH2 and MSH6 protein expression and MSI. The dosage ratio
was calculated as described above and a reduction of 40% or more indicated
that the transcript of one allele had decreased.
7.2 Long-range PCR (IV)
To determine the breakpoints for MLH1 deletion observed by MLPA, long-
range PCR was carried out using the Expand Long Template PCR System
(Roche Diagnostics, Mannheim, Germany). The fragments specific for the
mutant allele (1.1 kb) and wild-type allele (7.5 kb) were determined in an
agarose gel. The product corresponding to the mutant allele was cut out,
purified, and sequenced.
8 Statistical analysis (I-IV)
Statistical significance for differences between groups (p-value) was deter-
mined using Fisher’s or t test using VassarStats (http://faculty.vassar.edu/
lowry/VassarStats.html), as appropriate. All reported p-values were two-
tailed, and values less than 0.05 were considered significant.
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RESULTS
1 Mechanisms of somatic MMR gene inactivation
(I-IV)
1.1 LOH and acquired promoter methylation as second hits
In the Lynch syndrome associated tumors of stomach, urinary tract and
brain LOH was found to be the primary mechanism for the inactivation of
the second allele of MLH1 and MSH2. In Lynch syndrome associated gas-
tric cancers the frequency of LOH affecting the MLH1 gene was 50% (4/8).
On the contrary, in sporadic MSI gastric cancers the MLH1 inactivation
was probably due to MLH1 promoter methylation since it was present in
70% of the cases (7/10). Furthermore, the dosage ratio of MS-MLPA sug-
gested that both alleles were methylated. No significant MLH1 promoter
methylation was seen in the Lynch syndrome gastric cancers.
LOH of MLH1 also seemed to be an important mechanism for somatic
inactivation of the wild-type allele in Lynch syndrome associated brain
tumors. In urinary tract tumors, however, LOH accounted for somatic in-
activation mainly in urological tumors. In informative urinary tract tumors
LOH at MLH1 and MSH2 loci was observed in 83% (5/6) of MLH1 carriers
and in 100% (2/2) of MSH2 carriers, respectively. Only three cases were
available and informative among the brain tumors. LOH at the MLH1 lo-
cus was found in 67% of the cases (2/3) of which both were MLH1 mutation
carriers.
1.2 Mitotic recombination vs. gene conversion as a mecha-
nism of somatic inactivation
Based on the results obtained in study I, gene conversion was found to
be the mechanism of wild-type inactivation in a set of Lynch syndrome
tumors. Seven Finnish Lynch syndrome patients including four tumors
of colon, two endometrial tumors and one gastric cancer carrying germline
deletions of one or several exons of MSH2 or MLH1 were studied for somatic
deletions. All patients displayed MSI-H and six carried MLH1 deletion and
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one MSH2 deletion. The frequency of loss of heterozygosity as a second,
somatic event, in tumors was studied using MLPA. The somatic deletions
were mostly identical to the ones found in the germline. Biallelic deletion of
MLH1 was found in two of the four colon tumors (2/7, 29%), indicated by
the low dosage ratios in tumor tissue. The remaining tumors lacked somatic
deletions. In the 16 Swiss Lynch syndrome samples, biallelic deletions were
found in seven tumors, giving a total overall frequency of somatic deletions
of 50% (9/18) in this study, of which most were found in colorectal tumors
(6/11, 55%).
Eight highly polymorphic short tandem repeat markers flanking the
gene loci on chromosome 3 for MLH1 and chromosome 2 for MSH2 were
investigated to distinguish between the possible mechanisms leading to loss
of heterozygosity in the tumor. None of the tumors showed allelic loss at
the flanking markers at MLH1 and MSH2, indicating that a locus-restricted
event had occurred. Instead of mitotic recombination, gene conversion had
taken place in all cancers that were homozygous for the germline deletion.
2 Tumor spectrum in Lynch syndrome (II, III)
At present, cancer of stomach, bladder, brain and kidney are not included
in the tumor spectrum of Lynch syndrome according to Amsterdam cri-
teria. For a better understanding of carcinogenesis associated with Lynch
syndrome and deficient MMR in general, gastric, brain and urological car-
cinomas were molecularly characterized and compared with common tu-
mors, such as colorectal and endometrial tumors, from the same families.
The tumors (Figure 6) originated from a well-characterized series of Lynch
syndrome families from a nationwide registry with the predominant involve-
ment of MLH1 and a high rate of shared mutations. Exon 16 deletion of
MLH1, known as Mutation 1, was present in half of the families (Holmberg
et al., 1998).
2.1 MMR status in gastric cancer
The gastric cancers were from patients belonging to families with verified
Lynch syndrome and all families were known to have germline mutations
in the MMR genes. After initial screening, MMR gene germline mutations
were found in 87% (13/15) of Lynch syndrome associated gastric cancers.
All tumors with mutation were MSI-H and lacked MMR protein expression
corresponding to germline mutation. One MSH2 mutation carrier further
lacked expression of MSH6 protein (Schweizer et al., 2001). MLH1 was
the predisposing mutation in all but two cases, the remaining two being
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MSH2 mutation carriers. These tumors were mainly of intestinal histology
(12/13, 92% and 1 diffuse). Two out of 15 cancer patients did not to have
the predisposing MMR gene germline mutation of their families, giving a
phenocopy frequency of 13%. The phenotypes of these two patients were
identical to the other Lynch syndrome patients, however, these tumors were
MSS and showed no evidence of abnormal MMR protein expression.
Out of 46 sporadic gastric cancers, 10 tumors showed MSI-H and were
of intestinal histology. The sporadic intestinal MSI gastric cancers were
analyzed in comparison to Lynch syndrome gastric cancers, and all showed
loss of the MLH1 protein by immunohistochemistry. As described above,
the mechanism of MLH1 inactivation was found to be promoter methyla-
tion in 70% (7/10) of sporadic MSI gastric cancers in contrast to Lynch
syndrome gastric cancers.
2.2 MMR status urinary tract & brain tumors
All urinary tract and brain tumors from Lynch syndrome patients car-
ried MMR gene germline mutation, MLH1 being most commonly affected.
However, the relative share of MSH2 was higher among uroepithelial can-
cers of the bladder and ureter (3/10, 30%), and in brain tumors (3/7, 43%)
compared to for instance colorectal cancers (3/35, 9%) and endometrial
cancer (3/42, 7%). Urological cancer was rarely the first or only cancer
in the patients studied. All tumors of the urinary tract and brain lacked
the MMR protein corresponding to the germline mutation. Additionally,
the expected loss of MSH6 in the absence of the MSH2 protein was found
in 33% (4/12) tumors. The frequency of MSI varied greatly between the
different urinary tract and brain tumors. The frequency was highest in
ureter (5/5, 100%), intermediate in bladder (3/5, 60%) and low in kidney
and brain (1/4, 25% and 0/7, 0%, respectively). Brain tumors were stud-
ied with small-pool PCR, and appeared to have a different pattern of MSI,
observed by the presence of low share of unstable clones that was masked
by the normal alleles present.
2.3 Comparison of molecular profiles in Lynch syndrome
associated tumors
Ureter, stomach and colon tumors showed similar levels of MSI, whereas
MSI values of bladder tumors resembled those of endometrial tumors. In
brain tumors, no MSI was observed by standard PCR. Kidney carcinomas
were almost exclusively MSS. The difference is most likely due to tissue-
specific patterns of tumor growth (Kuismanen et al., 2002).
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As expected, frameshift mutations in mononucleotide repeats followed
the general MSI frequency in the tumors, as was seen in sporadic gas-
tric cancers. For example, ACVR2 frameshift mutations were significantly
more common in gastric and colorectal cancers compared to ureter cancer
(32/33, 97% vs. 1/5, 20%; p = 0.00033). PTEN inactivation is one of the
major genetic changes responsible for endometrial tumorigenesis. PTEN
involvement was characteristic of, and practically limited to, endometrial
carcinoma (Kuismanen et al., 2002, and Figure 6). The Wnt signaling
pathway is commonly deregulated in human carcinogenesis either due to
inactivating mutations in APC or activating mutations in CTNNB1 genes,
leading to the stabilization and accumulation of β-catenin in the nucleus.
Previous studies have implicated the role of the Wnt signaling pathway in
several types of tumors, both sporadic and hereditary (Giles et al., 2003).
Brain and urological tumors seldom displayed nuclear β-catenin in contrast
to gastrointestinal (stomach and colon) and endometrial carcinomas; the
difference between urinary tract (0/13, 0%) and gastrointestinal (stomach
and colon; 25/41, 61%) cancers and between urinary tract (0%) and en-
dometrial carcinomas (10/19, 53%) was statistically significant (p-values
0.000066 and 0.0016, respectively).
Strict or putative LOH at APC occurred significantly more often in the
urological samples (7/11, 64%), compared with colon cancers (2/14, 14%;
p = 0.016) or endometrial cancers (1/15, 7%; p = 0.0032). As APC -LOH,
however, showed a generally poor correlation with nuclear β-catenin in
the present series, APC -LOH may reflect general chromosomal instability
instead of providing a targeted mechanism to inactivate the wild-type copy
of APC. In the gastric cancer study, however, APC -LOH was found to
be frequent in intestinal gastric tumors independent of whether the tumor
was hereditary or sporadic and whether it was MSI or MSS (20/39, 51%),
and was significantly less common in diffuse gastric tumors (2/17, 12%,
p=0.001).
In contrast to the gastrointestinal and endometrial carcinomas, KRAS
mutations were absent in the brain and urinary tract tumors. The difference
between urinary tract cancers (0/14, 0%) and colon cancer (15/48, 31%)
was statistically significant (p = 0.028). Furthermore, KRAS mutations
were only found in MSI gastric carcinomas. Compared to gastrointestinal
cancers (6/41, 15%), p53 protein stabilization occurred at a similar rate in
brain tumors (1/6, 17%) but significantly more often in the urinary tract
cancers (33–75%, p = 0.0047).
Among 24 tumor suppressor genes examined for promoter methylation
(Figure 7), the highest average methylation frequencies were observed in the
colorectal (4.0) and gastric carcinomas (4.1), and the lowest in the urinary
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Figure 6: Summary of molecular data on MMR gene germline mutation-positive
cancers. Proportion of tumors with alterations is shown in percentage. ND, not
determined.
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Figure 7: Average number of methylated genes, out of 24 tumor suppressor
genes studied, per tumor.
tract (1.0–2.3; p = 0.010 relative to gastrointestinal tumors) and brain tu-
mors (1.4; p = 0.039 relative to gastrointestinal tumors). Promoter methy-
lation was significantly associated with MSI gastric cancers, when compared
to MSS gastric cancers. RASSF1 was one of the most commonly methy-
lated genes in the analyzed tumors, with the highest methylation frequen-
cies in kidney (75%) and endometrial carcinoma (71%). Except for kidney,
APC promoter 1A methylation was found in all carcinomas (especially in
stomach, colorectal and endometrial carcinoma, 48-62%), whereas no APC
methylation was detected in brain tumors. Some genes were methylated in
a tissue-specific manner (Table 6), for instance significant CD44 promoter
methylation was detected in kidney cancer only (75%). ESR1 methylation
was limited to adenocarcinomas (especially those of the gastrointestinal
tract) with no methylation in urothelial and brain tumors. The highest fre-
quency of GSTP1 promoter methylation was found in brain tumors (57%).
Table 6: Genes with promoter methylation in a minimum of 30% of tumors in
at least one tumor type. Numbers shown are percentages, bold numbers refer to
over 30% methylation.
Promoter Bladder Ureter Kidney Brain Stomach Colon Endometrium
RASSF1 20 60 75 43 23 30 71
APC 20 20 62 56 48
ESR1 25 46 56 10
CDH13 20 38 22 45
GSTP1 20 25 57 31 26 26
TIMP3 20 25 38 22 13
CD44 75 15 4
CHFR 54 22 3
PTEN 14 31 19
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3 Nature of germline defects in point mutation-
negative families suspected of Lynch syndrome
(IV)
It has previously been observed that in one-third of Lynch syndrome fami-
lies fulfilling the Amsterdam criteria and in a majority of those not fulfilling
these criteria, no mutations in the MMR genes are found, even after com-
prehensive mutation screening by advanced methods (Renkonen et al., 2003;
Holmberg et al., 1998). We searched for germline changes, i.e., the “first
hit”, in the MMR genes using deletion and methylation analyses in tumors
lacking MMR mutation.
3.1 Germline deletions and epimutations in Lynch syndrome
patients
All 45 index patients were suspected of having Lynch syndrome and were
mutation-negative by exon-specific genomic sequencing and specific testing
for the prevalent founder mutation (Mutation 1). They also lacked any
of the three MMR proteins in tumor tissue. Twelve out of 45 patients
(27%) were found to have large genomic rearrangements, of which four
patients (4/11, 36%) were from the research cohort and eight patients (8/34,
24%) from the clinic-based cohort. Deletions were present in 3/25 (12%),
9/16 (56%), and 0/4 (0%) among index patients lacking MLH1, MSH2,
or MSH6 expression, respectively. The difference in deletion frequency
between MLH1 and MSH2 was statistically significant (p = 0.0043).
Two patients with MLH1 protein loss in tumor tissue (one from each
cohort) showed a germline epimutation in MLH1. Of the five tested CpG-
containing regions, three were methylated in patient F36 and all in patient
N2. Among the index patients with MSH2 protein loss in tumor tissue, only
one displayed promoter methylation in a region that has not been associ-
ated with lost expression of MSH2 in the literature. Subsequent bisulphite
sequencing of the MSH2 promoter region around HhaI sites monitored by
MS-MLPA showed no evidence of methylation at the surrounding CpG
sites. There were no cases of MSH6 promoter methylation. The overall
frequency of epimutations was therefore 2/45 (4%) in our series.
In patient F36, methylation was found in blood, normal and tumor
tissue for three sites out of five studied MLH1 promoter regions, and the
higher methylation dosage ratio in tumor tissue implied somatic loss of
the unmethylated allele. Primer extension analysis revealed loss of the
wild-type allele in tumor DNA. Long-range PCR on genomic DNA from
blood of the same patient subsequently showed that the regions not showing
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methylation by MS-MLPA were located within a large genomic deletion
occurring in the same patient. In conclusion, patient F36 had both a large
genomic deletion and a germline epimutation, which overlapped in the same
allele, and the observed loss of expression from the mutant allele could result
from either change.
In patient N2, all five tested CpG-containing regions were methylated
in blood, normal colonic mucosa and colorectal tumor, and the dosage level
suggested monoallelic methylation. To prove that methylation affected one
allele and left the other allele intact, blood DNA from patient N2 was
subjected to bisulphite conversion, after which the promoter region was
amplified with methylation-unbiased primers (Suter et al., 2004), cloned,
and sequenced. Sequencing of the individual clones showed that either all
CpG sites or none were methylated, proving our hypothesis. The patient
was heterozygous for the c.655 polymorphism in MLH1 exon 8, which made
it possible to investigate the mRNA expression pattern of the two MLH1
alleles in blood; only one allele was expressed, thus the other allele was
silenced by methylation. Patient N2 displayed two different cancers of
the Lynch syndrome spectrum, both diagnosed at an early age, but the
family history was atypical. In addition, none of five first- or second- degree
relatives of N2 had the epimutation.
The present index patients with abnormal MLH1 or MSH2 expression
were divided into groups with and without large genomic deletions and
compared to index individuals from our nationwide registry known to carry
MLH1 or MSH2 point mutations. In both MLH1- and MSH2-associated
groups, deletion patients showed clearly stronger family histories than those
without deletions. An interesting feature of MSH2 point mutation carriers
was the predominance of distal over proximal colorectal tumors, and the
same was true for patients with large genomic deletions of MSH2 (p =
0.021 for difference between MLH1 and MSH2, with point mutation and
large deletion groups combined).
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DISCUSSION
1 Gastric, urinary tract and brain tumors & the
Lynch syndrome tumor spectrum
In order to include a given tumor in the Lynch syndrome tumor spectrum,
there should be increased evidence of the tumor type in Lynch syndrome
compared to the average population. Furthermore, evidence is necessary to
support the idea that a certain type of tumor from a MMR gene germline
mutation carrier has MMR deficiency as the driving force for tumorigenesis
(Watson and Riley, 2005).
All available gastric, urinary tract, and brain tumors were collected
from families known to have germline mutations in the MMR genes. We
started out by determining the mutation status of the respective patients in
order to exclude possible phenocopies. The phenocopy rate was 13% (2/15)
among patients with gastric cancers, and no phenocopies were found in the
patients with urinary tract and brain tumors. All subsequent molecular
analyses were based on verified MMR gene mutation carriers.
1.1 Gastric cancers
At present gastric cancer is not included in the Amsterdam II criteria
(Vasen et al., 1999), but is included in the revised Bethesda guidelines
(Umar et al., 2004a). An overall lifetime risk of gastric cancer by age 70
has been reported to vary between 4% and 19% in Lynch syndrome (Wat-
son et al., 2008; Vasen et al., 2001; Park et al., 2000; Aarnio et al., 1999;
Goecke et al., 2006). In Korea and China, gastric cancer is observed to be
the most common extracolonic cancer in Lynch syndrome families (Park et
al., 2000; Zhang et al., 2005), which probably reflects the high incidence of
gastric cancer in the general population of these countries.
Lynch syndrome associated gastric cancers analyzed in this study shared
many features of colorectal cancers from Lynch syndrome patients, such as
MSI-H, loss of MMR protein expression, high frequency of instability within
repeat-containing target genes (ACVR2, TGFβRII, MRE11A) and a high
number of methylated promoters (Planck et al., 2000; Kuismanen et al.,
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2002; Gonzalez-Aguilera et al., 2003; Schulmann et al., 2005). The Wnt-
signaling pathway is activated in 90% of sporadic colorectal cancers (Giles
et al., 2003) and is also found to be activated in about 65% of Lynch syn-
drome colorectal cancers (Miyaki et al., 1999). In the gastric cancers of the
present study, the Wnt pathway was found to be involved in nearly half
(27/59, 46%), through either alterations in β-catenin expression (nuclear
localization) or APC -LOH. Furthermore, LOH in the APC region was as-
sociated with intestinal histology regardless of MSI (p=0.007). Altogether,
these findings suggest that gastric cancers of Lynch syndrome are similar
in many ways to colorectal cancers, which are verified Lynch syndrome
tumors. Furthermore, the tumor profile of our Lynch syndrome gastric
cancers was compatible with MMR defect as the driving force shown by
MMR gene germline defect, MSI-H and loss of MMR protein expression,
suggesting that gastric cancers represent true Lynch syndrome spectrum
malignancies.
1.2 Urinary tract cancers
In the general population, bladder cancer is by far the most frequent cancer
of the urinary tract, whereas in Lynch syndrome renal pelvis and ureter
cancer, which are included in Amsterdam criteria II, are more common than
bladder cancer (Watson and Lynch, 1993; Aarnio et al., 1999; Vasen et al.,
1999). Sijmons et al. (1998) also noted an increased risk for transitional
cell cancer of the upper urinary tract in Lynch syndrome. In a recent study,
cancers of the urinary tract (kidney, renal pelvis, ureter or bladder) had
an overall lifetime risk of 8%, cancer risk rates were higher in males than
in females and 7-fold higher in MSH2 than in MLH1 associated families.
The lifetime risk estimate for male carriers in MSH2 families was nearly
28% (Watson et al., 2008). Aarnio et al. (1999) also found a higher risk
of bladder and ureter cancer (4%), compared to kidney cancer (3.3%) in
Lynch syndrome families.
The present study, ureter and bladder cancers from Lynch syndrome
families carried MMR gene germline mutation, lacked MMR protein ex-
pression and displayed MSI-H. In addition, our findings are compatible
with the available literature reports of four urothelial tumors of the ureter
or bladder from verified or putative carriers of MSH2 mutations (Hartmann
et al., 2003; Planck et al., 2000; Yuen et al., 2002; Mongiat-Artus et al.,
2006a) and five urothelial tumors of the ureter and renal pelvis from carri-
ers of a single MSH6 mutation (Wagner et al., 2001) that show high degree
MSI and/or MMR protein loss in these tumors as well. Kidney cancer, or
renal cell carcinoma, did however differ clearly from the other urinary tract
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tumors. Despite being from MMR gene germline mutation carriers, the tu-
mors were mainly MSS and stable at repeat-containing target genes. Our
findings suggest that uroepithelial cancers of the ureter (and bladder to a
lesser extent) share many features of tumorigenesis driven by MMR defi-
ciency, whereas renal cell carcinomas are unlikely to be part of the Lynch
syndrome tumor spectrum.
1.3 Brain tumors
Watson and Lynch (1993) did not find any excess risk of developing brain
tumor amongst Lynch syndrome families. However, Hamilton et al., (1995)
suggested a possible association between glioblastoma multiforme and Lynch
syndrome, i.e., Turcot syndrome. Vasen et al. (1996) found a statistically
significantly increased relative risk of brain tumors and concluded that brain
tumors belong to the tumor spectrum of Lynch syndrome. A recent study
noted that putative mutation carriers did not have a higher incidence of
disease than their first-degree relatives, hence these tumors were not consid-
ered to be associated with Lynch syndrome (Watson et al., 2008), despite
significant excess of brain tumors in Lynch syndrome reported relative to
the average population (Vasen et al., 1996; Aarnio et al., 1999; Vasen et al.,
1996).
The Lynch syndrome related brain tumors analyzed by us were MSS
despite MMR gene germline mutation, loss of wild-type copy and the as-
sociated loss of MMR protein expression. One explanation may be clonal
heterogeneity, i.e., occurrence of multiple subclones within the tumor (Bar-
netson et al., 2000). This could be the case in brain tumors as they dis-
played MSI when analyzed using small-pool PCR. MSI was not visible in a
standard PCR probably due to the presence of a minor share of clones with
instability and the majority of clones with normal alleles, thus resulting
in a MSS pattern. The brain tumors analyzed in our study lacked most
molecular alterations tested for, even the methylation pattern differed in
brain tumors from all other tumor types. Our data thus suggest different
pathways of tumorigenesis for brain tumors compared to other tumors from
Lynch syndrome families.
1.4 Overall conclusion
Colorectal and endometrial cancers have been studied extensively in Lynch
syndrome families. Here we used colorectal and endometrial cancers, which
are unequivocal components of the Lynch syndrome tumor spectrum, as
comparison for the less common tumors of Lynch syndrome families. All
colorectal cancers displayed MMR gene germline mutation and nearly all
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displayed loss of MMR protein expression and MSI-H. Gastric cancer and
uroepithelial tumors of the ureter and bladder shared several features of
Lynch syndrome colorectal cancers. In contrast, tumors of the brain and
kidney were mainly MSS despite loss of MMR protein expression. This
suggests that brain tumors and kidney adenocarcinomas develop through
different pathways.
2 Differences and similarities between Lynch syn-
drome and sporadic cancer
Microsatellite instability, resulting from an MMR defect, is found at high
frequencies in tumors of Lynch syndrome patients and is also present to
a lesser degree in sporadic tumors (Peltomaki, 2003). The frequency of
MSI varies according to tissue, with high general fluctuation. As expected,
the MSI frequencies were generally higher in our Lynch syndrome tumors
compared to findings in literature on their sporadic counterparts (Table 7).
Brain and kidney tumors were exceptions, displaying roughly equal MSI
frequencies in sporadic vs. Lynch syndrome tumors. Another difference
between sporadic and Lynch syndrome tumors is the mechanism of inac-
tivation of the wild-type allele. In MSI sporadic cancer, MLH1 promoter
methylation is a major mechanism, whereas LOH of MMR genes predomi-
nates in Lynch syndrome tumors (Ollikainen et al., 2007; Pinto et al., 2008;
Leung et al., 1999; Fleisher et al., 1999; Suzuki et al., 1999; Carvalho et al.,
2003).
In the literature, the frequencies of MSI in sporadic gastric cancer ranges
from 5 to 50% (Zaky et al., 2008; Ottini et al., 2006; Bacani et al., 2005; Oda
et al., 2005), whereas our Lynch syndrome gastric cancers displayed MSI
in all cases studied. The Lynch syndrome gastric cancers analyzed in this
study closely resembled sporadic intestinal MSI gastric cancers, except that
MLH1 promoter methylation was absent and general epigenetic changes
less frequent, suggesting similar but not identical developmental pathways.
Similar to our findings on sporadic gastric cancer, Falchetti et al. (2008)
observed in their sporadic gastric cancers that MSI-H was associated with
the intestinal type, according to the Lauren classification, and that MSI-
H was strongly associated with loss of MLH1 expression. In agreement
with the general notion discussed above, in sporadic intestinal MSI gastric
cancer, biallelic methylation of MLH1 appeared to be the mechanism of
MMR inactivation, whereas in Lynch syndrome gastric cancers somatic
inactivation of MLH1 was LOH.
The bladder and ureter tumors included in this study showed MSI fre-
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Table 7: MSI in different tissues in tumors from Lynch syndrome vs. sporadic
tumors.
Lynch syndrome Sporadic Reference
Tissue (our data) (literature)
Stomach 100% 5 - 50% (Oda et al., 2005; Zaky et al., 2008;
Ottini et al., 2006; Bacani et al.,
2005)
Ureter 100% 4 - 27% (Roupreˆt et al., 2005; Ericson et
al., 2005; Hartmann et al., 2003;
Hartmann et al., 2002; Catto et al.,
2003; Mongiat-Artus et al., 2006)
Colorectum 96% 15 - 25% (Boland et al., 1998)
Endometrium 63% 9 - 45% (Caduff et al., 1996; MacDonald et
al., 2000)
Bladder 60% 0 - 10% (Gonzalez-Zulueta et al., 1993;
Catto et al., 2003)
Kidney 25% 8 - 18% (Uchida et al., 1994; Diakoumis
et al., 1998; Leach et al., 2002;
Thrash-Bingham et al., 1995)
Brain 0% 0 - 30% (Zhu et al., 1996; Lundin et al.,
1998; Malmer et al., 2001; Szybka
et al., 2003; Eckert et al., 2007;
Martinez et al., 2007)
quencies that exceed those reported for the corresponding sporadic tumors
(Gonzalez-Zulueta et al., 1993; Hartmann et al., 2002; Hartmann et al.,
2003; Catto et al., 2003; Ericson et al., 2005; Roupret et al., 2005; Mongiat-
Artus et al., 2006b). This may indicate that somatic MMR inactivation is
a minor pathway in the development of sporadic upper urothelial cancer
(Ericson et al., 2005). The occurrence of MSI in sporadic kidney cancer
in literature and our Lynch syndrome associated kidney cancer was rare
(Uchida et al., 1994; Diakoumis et al., 1998; Thrash-Bingham et al., 1995;
Leach et al., 2002). Additionally, loss of function of MLH1 and MSH2 does
not usually occur in sporadic kidney cancer, either by promoter methyla-
tion or exonic mutation (Rubio-Del-Campo et al., 2008). Together with the
infrequent occurrence of MSI in sporadic renal cell carcinomas, our find-
ings suggest that renal cell carcinomas are unlikely to be part of Lynch
syndrome, contrary to ureter and possibly bladder carcinoma.
In contrast to brain tumors analyzed in this study where no MSI was
observed by standard PCR, MSI frequencies for sporadic gliomas have been
reported to range up to 30% (Zhu et al., 1996; Lundin et al., 1998; Malmer
et al., 2001; Szybka et al., 2003; Eckert et al., 2007; Martinez et al., 2007),
and is reported to be absent or rare in gangliogliomas [0%, (Zhu et al.,
1996)] and meningiomas [1–2%, (Zhu et al., 1996; Kirsch et al., 1997)].
However, nearly all Lynch syndrome brain tumors we studied displayed
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loss of MMR protein corresponding to germline mutation, whereas in other
studies loss of MMR protein expression is reported to be infrequent in brain
tumors (Eckert et al., 2007; Martinez et al., 2007).
3 Germline defects in mutation-negative Lynch
syndrome patients
We found large genomic deletions in nearly a third of the tumors from
suspected Lynch syndrome families, not including the Finnish founder mu-
tation (MLH1 del ex16; Nystrom-Lahti et al., 1995) which was excluded at
the outset. Our frequency is in the upper range of deletion rates reported
for comparable series in literature (Gille et al., 2002; Baudhuin et al., 2005;
Grabowski et al., 2005; Pistorius et al., 2007). Germline epimutations in
MLH1 were found in two patients (4%), the frequency being in the range
of previous studies (Gazzoli et al., 2002; Miyakura et al., 2004; Hitchins et
al., 2007; Valle et al., 2007). Even though methylation in our epimutation
carriers was found to be present in all tested tissues (blood, normal mucosa
and colorectal cancer), it did not show evidence of heritability, because
epimutation was absent in studied first- and second-degree relatives. Some
studies provide evidence of heritability or transgenerational epigenetic in-
heritance of germline epimutation (Chan et al., 2006; Hitchins et al., 2007).
The remaining investigations indicate the absence of epimutation in other
family members (Suter et al., 2004; Miyakura et al., 2004; Valle et al., 2007;
Hitchins et al., 2005). Morak et al. (2008) described MLH1 epimutation
cases that were compatible with either heritability, de novo methylation,
mosaic or incomplete methylation, or lack of heritability.
No genetic or epigenetic germline defect was detectable in nearly half
of our cases with lost MSH2 protein and in a majority of MLH1 or MSH6-
associated cases, leaving their genetic etiology unknown. Wagner et al.
(2002) described a Lynch syndrome family caused by an inversion disrupt-
ing the MSH2 gene. Hence, certain structural alterations, such as inver-
sions, as well as regulatory changes in non-coding regions (Shin et al., 2002)
remain theoretical possibilities for MMR gene inactivation. Loss of PMS2
protein in tumor tissue could point to germline mutations in PMS2, which
have been found to account for 5% of Lynch syndrome cases, however, the
penetrance appears to be lower than that for the other MMR genes (Clen-
denning et al., 2008; Truninger et al., 2005; Hendriks et al., 2006). In our
study, the instability of PMS2 was probably secondary to the loss of MLH1,
since all cases with absent PMS2 also lacked MLH1 (Chang et al., 2000).
As we generally did not have tumor samples available from several affected
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family members, we were unable to evaluate concordance for immunohis-
tochemical staining patterns and MSI within families. It is possible that
MMR gene silencing in tumor tissue occasionally resulted from completely
somatic mechanisms, since most of our cases only met the revised Bethesda
guidelines at best. In our research cohort we had tumor samples avail-
able and found that, at least for MLH1, somatic hypermethylation was a
probable mechanism for MMR gene silencing.
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CONCLUSIONS &
FUTURE PROSPECTS
Despite origin from verified MMR gene mutation carriers, the frequency of
high-level microsatellite instability in tumors varied between high (100–96%
for ureter, stomach and colon), intermediate (63-60% for endometrium and
bladder) and low (25-0% for kidney and brain). Also, promoter methyla-
tion of tumor suppressor genes distinguished the tumors in an organ-specific
manner. Whereas, all Lynch syndrome colorectal cancers displayed MMR
gene germline mutation and nearly all displayed loss of MMR protein ex-
pression and MSI-H, tumors of brain and kidney were mainly MSS, despite
loss of MMR protein expression. This suggests that brain tumors and kid-
ney adenocarcinomas develop through different pathways. On the other
hand, gastric cancer and uroepithelial tumors of ureter and bladder shared
several features of Lynch syndrome colorectal cancers.
Gene conversion has been described as a mechanism of both germline
and somatic inactivation of genes (Cavenee et al., 1983), but little is known
about its role in cancer (Chen et al., 2007). Analysis of cancer specimens
from two independent sets of Swiss and Finnish MLH1 /MSH2 deletion
carriers revealed that somatic deletions nearly identical to the ones in
the germline occur frequently in colorectal cancers. Chromosome-specific
marker analysis further implied that loss of the wild-type allele predomi-
nantly occurred through locus-restricted recombinational events, i.e., gene
conversion, rather than mitotic recombination or deletion of the respective
gene locus. This may be helpful for the identification of germline mutations
of the MMR genes.
Large genomic deletions (mainly MSH2 ) may explain a significant pro-
portion and germline epimutations (in MLH1 ) a smaller fraction of point
mutation-negative families/cases with MMR protein loss in tumor tissue.
In contrast to genomic deletions, which are associated with strong fam-
ily histories for Lynch syndrome, epimutations occurred in patients with
multiple early-onset tumors without any significant family history. Still
no genetic or epigenetic germline defect was detectable in almost half of
the cases suspected of Lynch syndrome with lost MMR protein expression,
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leaving their genetic etiology unknown. Further characterization of these
tumors is necessary to identify the underlying defects to improve the diag-
nosis, counseling, and management of the patients and their families.
The same approach as used for gastric, urinary tract and brain tumors in
the present study could be performed to investigate the possible association
of other tumors in Lynch syndrome, such as breast cancer. Breast cancer
has also been observed in Lynch syndrome family members and, in some
cases, the inherited mismatch repair gene mutation has been shown to have
played a role in its development (Vasen et al., 2001; Boyd et al., 1999).
Other studies provide no evidence that Lynch syndrome cases are at higher
risk for breast cancer than members of the general population (Watson et
al., 2008). Hence, Lynch syndrome-associated elevation of breast cancer
risk has not been convincingly demonstrated and therefore, it would be
important to further study the role of breast cancer in Lynch syndrome.
Germline epimutations in tumor suppressor genes other than MMR
genes may be interesting to study as possible contributing mechanisms to
non-syndromic types of familial cancer where no clear underlying mech-
anism has yet been found. Since germline epimutations lack a uniform
pattern of inheritance (Morak et al., 2008) and present with rather diverg-
ing clinical characteristics, they could hence serve plausible explanations
for non-syndromic types of hereditary cancer. Also, the availability of new
methods, such as MS-MLPA, to study the role of epigenetics in tumor
development, enables screening of several tumor suppressor genes simulta-
neously.
In conclusion, this study provides better understanding of Lynch syn-
drome associated tumors, particularly gastric cancer, urinary tract can-
cers and brain tumors. Gastric cancer was observed to be a true Lynch
syndrome tumor with MMR deficiency as the driving force of tumorigene-
sis. The uroepithelial tumors of bladder and ureter displayed MMR gene
germline mutation and subsequent loss of MMR protein and high frequency
MSI, compatible with MMR tumorigenesis. Brain tumors and kidney car-
cinoma, on the other hand, were mostly MSS despite MMR gene mutation
and loss of protein expression, implying the possibility of alternative routes
of tumor development. The findings of the present study present possible
implications in clinical cancer surveillance.
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